BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Point mutations in the kinase domain of BCR-ABL are the most common mechanism of drug resistance in chronic myeloid leukemia (CML) patients treated with ABL kinase inhibitors, including imatinib. It has also been shown in vitro that mutations outside the kinase domain in the neighboring linker, SH2,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sherbenou, Daniel W., Hantschel, Oliver, Kaupe, Ines, Willis, Stephanie, Bumm, Thomas, Turaga, Lalita P., Lange, Thoralf, Dao, Kim-Hien, Press, Richard D., Druker, Brian J., Superti-Furga, Giulio, Deininger, Michael W.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2010
Teme:
Myeloid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2995357/
https://ncbi.nlm.nih.gov/pubmed/20519627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-10-183665
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items